Quinagolide - A valuable treatment option for hyperprolactinaemia

European Journal of Endocrinology

Volumn 154, Issue 2, 2006, Pages 187-195

  Barlier, Anne ^a   Jaquet, Philippe ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; PROLACTIN; QUINAGOLIDE;

ADENOMA; AMENORRHEA; BINDING AFFINITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TOLERABILITY; ERYTHROMELALGIA; GALACTORRHEA; HEALTH HAZARD; HUMAN; HYPERPROLACTINEMIA; IMPOTENCE; LUNG FIBROSIS; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; NAUSEA; OLIGOMENORRHEA; OSTEOPOROSIS; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; PROLACTINOMA; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; SYMPTOMATOLOGY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VASOSPASM;

ADMINISTRATION, ORAL; AMINOQUINOLINES; BROMOCRIPTINE; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; PATIENT COMPLIANCE;

EID: 33644595738     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02075     Document Type: Review

References (67)

1. Verhelst J & Abs R. Hyperprolactinemia: pathophysiology and management. Treatments in Endocrinology 2003 2 23-32.
2. Mah PM & Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Seminars in Reproductive Medicine 2002 20 365-374.
3. Luciano AA. Clinical presentation of hyperprolactinemia. Journal of Reproductive Medicine 1999 44 1085-1090.
4. Colao A, De Rosa M, Sarnacchiaro F, Di Sarno A, Landi ML, Iervolino E, Zarrilli S, Merola B & Lombardi G. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. European Journal of Endocrinology 1996 135 548-552.
5. Vartej P, Poiana C & Vartej I. Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women. Gynecological Endocrinology 2001 15 43-47.
6. Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT & McArthur JW. Decreased bone density in hyperprolactinemic women. New England Journal of Medicine 1980 303 1511-1514.
7. Klibanski A & Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. New England Journal of Medicine 1986 315 542-546.
8. Bankowski BJ & Zacur HA. Dopamine agonist therapy for hyperprolactinemia. Clinical Obstetrics and Gynecology 2003 46 349-362.
9. Kletzky OA & Vermesh M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertility and Sterility 1989 51 269-272.
10. Ginsburg J, Hardiman P & Thomas M. Vaginal bromocriptine-clinical and biochemical effects. Gynecological Endocrinology 1992 6 119-126.
11. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A & Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. European Journal of Endocrinology 1996 135 413-420.
12. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P & Enjalbert A. Resistance to bromocriptine in prolactinomas. Journal of Clinical Endocrinology and Metabolism 1989 69 500-509.
13. Brue T, Pellegrini I, Priou A, Morange I & Jaquet P. Prolactinomas and resistance to dopamine agonists. Hormone Research 1992 38 84-89.
14. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I & Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New England Journal of Medicine 1994 331 904-909.
15. Homburg R, West C, Brownell J & Jacobs HS. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clinical Endocrinology (Oxford) 1990 32 565-571.
16. Glaser B, Nesher Y & Barziliai S. Long-term treatment of bromo- criptine-intolerant prolactinoma patients with CV 205-502. Journal of Reproductive Medicine 1994 39 449-454.
17. van der Lely AJ, Brownell J & Lamberts SW. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. Journal of Clinical Endocrinology and Metabolism 1991 72 1136-1141.
18. Schultz PN, Ginsberg L, McCutcheon IE, Samaan N, Leavens M & Gagel RF. Quinagolide in the management of prolactinoma. Pituitary 2000 3 239-249.
19. Rohmer V, Freneau E, Morange I & Simonetta C. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse. Annals of Endocrinology (Paris) 2000 61 411-417.
20. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J & Kuhn JM. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clinical Endocrinology (Oxford) 1991 34 25-29.
21. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G & Colao A. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology (Oxford) 2000 53 53-60.
22. Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Ferone D, Selleri A, Landi ML, Schettini G, Nappi C et al. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecological Endocrinology 1994 8 175-181.
23. Delgrange E, Maiter D & Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. European Journal of Endocrinology 1996 134 454-456.
24. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L & Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 876-883.
25. McDonald WM, Sibley DR, Kilpatrick BF & Caron MG. Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Molecular and Cellular Endocrinology 1984 36 201-209.
26. Closse A, Camps M, Wanner A & Palacios JM. In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist (3H)CV 205-502. Brain Research 1988 440 123-132.
27. Del Dotto P & Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clinical Pharmacokinetics 2003 42 633-645.
28. Factor SA. Dopamine agonists. Medical Clinics of North America 1999 83 415-443, vi-vii.
29. Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 2000 68 685-689.
30. Rasmussen C, Brownell J & Bergh T. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinologica (Copenhagen) 1991 125 170-176.
31. Gaillard RC, Abeywickrama K, Brownell J & Muller AF. Specific effect of CV 205-502, a potent nonergot dopamine agonist, during a combined anterior pituitary function test. Journal of Clinical Endocrinology and Metabolism 1989 68 329-335.
32. Rasmussen C, Bergh T, Wide L & Brownell J. CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion. Clinical Endocrinology (Oxford) 1987 26 321-326.
33. Thorner M, Fluckiger E & Calne D. Bromocriptine, a clinical and pharmacological review. New York: Raven Press, 1980.
34. Hawkins T. Impact of once- and twice-daily dosing regimens on adherence and overall safety. AIDS Reader 2004 14 320-322, 324, 329-331, 334-326.
35. Moyle G. Once-daily therapy: less is more. International Journal of STD and AIDS 2003 14 1-5.
36. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clinical Therapeutics 1984 6 592-599.
37. Claxton AJ, Cramer J & Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 2001 23 1296-1310.
38. Ciccarelli E, Mazza E, Ghigo E, Guidoni F, Barberis A, Massara F & Camanni F. Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia. Journal of Endocrinological Investigation 1987 10 51-53.
39. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G & Scanlon MF. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clinical Endocrinology (Oxford) 1997 46 409-413.
40. van der Heijden PF, de Wit W, Brownell J, Schoemaker J & Rolland R. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. European Journal of Obstetrics, Gynecology, and Reproductive Biology 1991 40 111-118.
41. van der Heijden PF, Rolland R, Thomas CM & Brownell J. Endocrine effects of CV 205-502, a new dopamine agonist, in hyperprolactinemic women. Gynecological Endocrinology 1988 2 233-248.
42. van der Heijden PF, Lappohn RE, Corbey RS, de Goeij WB, Brownell J & Rolland R. The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study. Fertility and Sterility 1989 52 574-579.
43. Shoham Z, Homburg R & Jacobs HS. CV 205-502-effectiveness, tolerability, and safety over 24-month study. Fertility and Sterility 1991 55 501-506.
44. Barnett PS, Palazidou E, Miell JP, Coskeran PB, Butler J, Dawson JM, Maccabe J & McGregor AM. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502. Quarterly Journal of Medicine 1991 81 891-906.
45. Serri O, Beauregard H, Lesage J, Pedneault L, Comtois R, Jilwan N, Somma M, Vachon L & Brownell J. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas. Journal of Clinical Endocrinology and Metabolism 1990 71 682-687.
46. Vance ML, Cragun JR, Reimnitz C, Chang RJ, Rashef E, Blackwell RE, Miller MM & Molitch ME. CV 205-502 treatment of hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism 1989 68 336-339.
47. Khalfallah Y, Claustrat B, Grochowicki M, Flocard F, Horlait S, Serusclat P & Sassolas G. Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas. Journal of Clinical Endocrinology and Metabolism 1990 71 354-359.
48. Vance ML, Lipper M, Klibanski A, Biller BM, Samaan NA & Molitch ME. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Annals of Internal Medicine 1990 112 668-673.
49. Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, Enjalbert A & Jaquet P. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. Journal of Clinical Endocrinology and Metabolism 1992 74 577-584.
50. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G & Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. Journal of Clinical Endocrinology and Metabolism 2001 86 5256-5261.
51. De Luis DA, Becerra A, Lahera M, Botella JI, Valero & Varela C. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. Journal of Endocrinological Investigation 2000 23 428-434.
52. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G & Lombardi G. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. Journal of Clinical Endocrinology and Metabolism 1998 83 2777-2780.
53. Giusti M, Porcella E, Carraro A, Cuttica M, Valenti S & Giordano G. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. Journal of Endocrinological Investigation 1994 17 51-57.
54. Rains CP, Bryson HM & Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995 49 255-279.
55. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR & Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Journal of Clinical Endocrinology and Metabolism 1996 81 2338-2343.
56. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L & Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. Journal of Clinical Endocrinology and Metabolism 2000 85 2247-2252.
57. Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni F & Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. Journal of Clinical Endocrinology and Metabolism 1989 69 725-728.
58. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C & Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism 1999 84 2518-2522.
59. Krupp P & Monka C. Bromocriptine in pregnancy: safety aspects. Klinische Wochenschrift 1987 65 823-827.
60. Czeizel A, Kiss R, Racz K, Mohori K & Glaz E. Case-control cytogenetic study in offspring of mothers treated with bromocriptine during early pregnancy. Mutation Research 1989 210 23-27.
61. Raymond JP, Goldstein E, Konopka P, Leleu ME, Merceron RE & Loria Y. Follow-up of children born of bromocriptine-treated mothers. Hormone Research 1985 22 239-246.
62. Chiodini I & Liuzzi A. PRL-secreting pituitary adenomas in pregnancy. Journal of Endocrinological Investigation 2003 26 96-99.
63. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Safety 1996 14 228-238.
64. de Wit W, Coelingh Bennink HJ & Gerards LJ. Prophylactic bromocriptine treatment during pregnancy in women with macroprolactinomas: report of 13 pregnancies. British Journal of Obstetrics and Gynaecology 1984 91 1059-1069.
65. Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S, Cammarota T, Camanni M & Camanni F. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. Journal of Endocrinological Investigation 1997 20 547-551.
66. Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, Rocchi F, Gangi E, Paracchi S, Gasperi M, Lavezzari M, Nicolosi AE, Ferrero S, Landi ML, Beck-Peccoz P & Bonati M. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reproductive Toxicology 2002 16 791-793.
67. Webster J. Clinical management of prolactinomas. Baillieres Best Practice and Research in Clinical and Endocrinological Metabolism 1999 13 395-408.